The Pro Medicus (ASX:PME) share price is surging 5% on Thursday

This ASX biotech share is having a strong day of trade

| More on:
Group of medical professionals high five

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price is surging higher on Thursday. Shares in the Aussie biotech group have climbed more than 5% in a sharp rebound from Wednesday's session.

At the time of writing, the Pro Medicus share price is up 4.05%, trading at $54.71.

What's with the Pro Medicus share price today?

Today's share price move hasn't been sparked by any news or announcements from the Aussie healthcare group. In fact, Pro Medicus hasn't released any ASX announcements at all since September 2.

However, that hasn't stopped investors piling into the company's shares and bidding up the Pro Medicus share price on Thursday.

It's possible today's moves are a rebound after shares in the ASX healthcare informatics group slumped lower yesterday. The company's shares have been under pressure amid broader weakness in the healthcare and technology sectors.

While yesterday had signs of profit-taking after year to date gains above 50%. Any fears of extended losses have subsided for now, however, as momentum has returned to the healthcare group's shares on Thursday.

A rising tide?

There is also the old 'rising tide raises all ships' adage that could be at play. The S&P/ASX 200 Index (ASX: XJO) has added 1.82% at the time of writing in a good day for Aussie investors.

Strong investor sentiment could be playing its part with the Pro Medicus share price roaring back to life after a disappointing day of trade on Wednesday.

It's yet another day of gains in what is shaping up to be a good year for shareholders. Despite somewhat stagnating earlier this year, the company's value has been steadily climbing since May.

Steady gains appear to have been supported by new contract signings including an 8-year, $14 million deal with The University of Vermont.

Foolish takeaway

It looks like the good times just keep on rolling for the Pro Medicus share price. Shares in the ASX biotech have now more than doubled in the last 12 months with gains of 104%.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »

Excited elderly woman on a swing.
Healthcare Shares

Guess which ASX 300 healthcare share is lifting off on $25 million news

The ASX 300 healthcare share is grabbing investor interest on Thursday. Let’s see why.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Doomed takeover bid for Mayne Pharma to come to an end

The Mayne Pharma takeover saga appears to be finally drawing to an end, with shareholders bearing the pain of the…

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Is this ASX healthcare stock a buy low candidate after falling 35%?

One broker is tipping big upside.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

New biotech company set to list after $231 million initial public offer

Saluda Medical will list on the ASX this week after raising more than $230 million to drive sales growth for…

Read more »

Man holding fifty Australian Dollar banknote in his hands, symbolising dividends, symbolising dividends.
Healthcare Shares

Here's the dividend forecast out to 2030 for CSL shares

How healthy could the dividends be in the coming years?

Read more »